Detalhe da pesquisa
1.
Nivolumab, nivolumab-ipilimumab, and VEGFR-tyrosine kinase inhibitors as first-line treatment for metastatic clear-cell renal cell carcinoma (BIONIKK): a biomarker-driven, open-label, non-comparative, randomised, phase 2 trial.
Lancet Oncol
; 23(5): 612-624, 2022 05.
Artigo
em Inglês
| MEDLINE | ID: mdl-35390339
2.
Cabozantinib-nivolumab sequence in metastatic renal cell carcinoma: The CABIR study.
Int J Cancer
; 151(8): 1335-1344, 2022 10 15.
Artigo
em Inglês
| MEDLINE | ID: mdl-35603906
3.
EULAR recommendations for the role of the nurse in the management of chronic inflammatory arthritis.
Ann Rheum Dis
; 71(1): 13-9, 2012 Jan.
Artigo
em Inglês
| MEDLINE | ID: mdl-22039168
4.
Open-label phase II to evaluate the efficacy of NEoadjuvant dose-dense MVAC In cOmbination with durvalumab and tremelimumab in muscle-invasive urothelial carcinoma: NEMIO.
Bull Cancer
; 107(5S): eS8-eS15, 2020 Jun.
Artigo
em Inglês
| MEDLINE | ID: mdl-32620213
5.
BIONIKK: A phase 2 biomarker driven trial with nivolumab and ipilimumab or VEGFR tyrosine kinase inhibitor (TKI) in naïve metastatic kidney cancer.
Bull Cancer
; 107(5S): eS22-eS27, 2020 Jun.
Artigo
em Inglês
| MEDLINE | ID: mdl-32620212